Shikha Wadhwani, MD, MS

IgAN arises through a multi-hit process, and each therapeutic class acts at a different step. Dr. Cheung maps mucosal B-cell priming, plasma cells, complement, and kidney-protective therapies onto the pathway.

Guidelines now call for treating the immune driver of disease and providing supportive care at the same time. The panel considers how ambitious targets have become realistic, and why access still limits what clinicians can offer.

Despite new therapies, IgAN still progresses to kidney failure in most patients. The panel reviews who is at greatest risk, which targets matter, and how hematuria fits alongside proteinuria and eGFR.

Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.

Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

Brendan Neuen, MBBS, PhD, joins Shikha Wadhwani, MD, MS, to unpack FIND-CKD's GN subgroup data and 23% risk reduction.

VISIONARY enrolled 510 high-risk IgAN patients globally. Learn how the trial's design and anti-APRIL mechanism were built to target disease at its root.

Dana Rizk, MD, joins hosts Brendon Neuen and Shikha Wadhwani to unpack 2-year VISIONARY data showing sibeprenlimab stabilizes eGFR in IgAN.

Martin de Borst, MD, PhD, discusses IV iron use in transplant recipients through an RCT focused on exercise capacity, function, and quality of life.

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

Hiddo Heerspink, MD, PhD, highlights ASSIST trial data showing atrasentan reduced proteinuria by 25% on top of SGLT2 inhibitors in IgA nephropathy.

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

In the final segment of this 5-part HCPLive RX Review, experts discuss real-world barriers to implementing new C3G therapies and lingering unmet needs.

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

From new data for potential IgAN treatments to the use of combination initiation therapy for type 2 diabetes and CKD, here are 5 key updates from the annual meeting.

A deep dive into several noteworthy IgAN studies presented during the ERA 2025 Congress.

Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.

In the final segments of this 4-part episode, the discussion focuses on the use of HCEs in different kidney disease trials.

In part 3 of 4 from this episode, the discussion focuses on potential limitations to HCEs and addressing skepticism around their use in nephrology.

In part 2 of 4 from this episode, the discussion focuses on hierarchical composite endpoints and their use in nephrology trials and research.

In part 1 of 4 from this episode, the discussion focuses on traditional composite endpoints in nephrology trials and the use of HCEs.